|
Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data |
Fizazi K, Le Maitre A, Hudes G, Berry W R, Kelly W K, Eymard J C, Logothetis C J, Pignon J P, Michiels S |
|
|
Record Status This is a systematic review that meets the criteria for inclusion on DARE. Bibliographic details Fizazi K, Le Maitre A, Hudes G, Berry W R, Kelly W K, Eymard J C, Logothetis C J, Pignon J P, Michiels S. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncology 2007; 8(11): 994-1000 Indexing Status Subject indexing assigned by NLM MeSH Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols /adverse effects /therapeutic use; Castration; Disease-Free Survival; Drug Resistance, Neoplasm; Estramustine /administration & Follow-Up Studies; Humans; Male; Middle Aged; Prostate-Specific Antigen /blood; Prostatic Neoplasms /blood /drug therapy /mortality; Randomized Controlled Trials as Topic /statistics & Survival Rate; dosage /adverse effects; numerical data AccessionNumber 12007003841 Date bibliographic record published 09/08/2008 |
|
|
|